Want to see HK:3692 full AI Analyst Report?
Top Page
Hansoh Pharmaceutical Group Company Limited
(3692)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$32.00
â–Ľ(-19.52% Downside)
Action:Reiterated
Date:05/02/26
The score is primarily driven by strong financial performance (high profitability, very low leverage, and solid 2025 cash generation). Offsetting this are mixed/weak technical signals and a relatively expensive valuation (high P/E with low yield).
Positive Factors
High Profitability / Margins
Sustained very high gross and healthy net margins indicate durable pricing power for branded drugs and efficient manufacturing. That margin profile supports reinvestment in R&D, funds marketing for new launches, and creates a durable earnings buffer versus cost shocks over a multi‑quarter horizon.
Negative Factors
Margin & Cash Conversion Volatility
Historic swings in operating cash conversion and margins reduce predictability of free cash flow and complicate budgeting for R&D and commercialization. Such volatility can impair long-term planning, increase funding needs in down years, and raises forecasting risk for investors and management alike.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability / Margins
Sustained very high gross and healthy net margins indicate durable pricing power for branded drugs and efficient manufacturing. That margin profile supports reinvestment in R&D, funds marketing for new launches, and creates a durable earnings buffer versus cost shocks over a multi‑quarter horizon.
Read all positive factors
Hansoh Pharmaceutical Group Company Limited (3692) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$173.80B
Dividend Yield0.97%
Average Volume (3M)9.67M
Price to Earnings (P/E)28.2
Beta (1Y)0.52
Revenue Growth22.62%
EPS Growth26.23%
CountryHK
Employees9,347
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.15Price Target Upside16.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)0.98
Revenue Forecast (FY)HK$16.93B
Hansoh Pharmaceutical Group Company Limited Business Overview & Revenue Model
Company Description
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic area...
How the Company Makes Money
Hansoh primarily makes money by selling proprietary/branded prescription drugs. Revenue is generated when the company manufactures finished pharmaceutical products (and in some cases active pharmaceutical ingredients) and sells them to hospitals, ...
Hansoh Pharmaceutical Group Company Limited Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
93
Very Positive
Cash Flow
86
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.03B | 12.26B | 10.10B | 9.38B | 9.94B |
| Gross Profit | 13.51B | 11.16B | 9.07B | 8.51B | 9.06B |
| EBITDA | 5.77B | 4.28B | 4.20B | 2.93B | 3.08B |
| Net Income | 5.56B | 4.37B | 3.28B | 2.58B | 2.71B |
Balance Sheet | |||||
| Total Assets | 39.92B | 31.66B | 33.04B | 30.00B | 27.16B |
| Cash, Cash Equivalents and Short-Term Investments | 31.58B | 23.39B | 24.86B | 21.63B | 18.94B |
| Total Debt | 105.14M | 117.89M | 4.30B | 4.38B | 3.83B |
| Total Liabilities | 4.54B | 2.98B | 7.24B | 7.35B | 7.13B |
| Stockholders Equity | 35.38B | 28.68B | 25.79B | 22.65B | 20.03B |
Cash Flow | |||||
| Free Cash Flow | 6.25B | 3.64B | 2.90B | 2.47B | 2.12B |
| Operating Cash Flow | 6.74B | 3.86B | 3.12B | 2.74B | 2.58B |
| Investing Cash Flow | -7.15B | -1.39B | 1.07B | -5.94B | -2.26B |
| Financing Cash Flow | 1.55B | -6.07B | -753.70M | -818.14M | 3.42B |
Hansoh Pharmaceutical Group Company Limited Technical Analysis
Negative
39.76
Price Trends
33.88
Negative
34.61
Negative
36.33
Negative
Market Momentum
-1.24
Negative
28.24
Positive
15.83
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3692, the sentiment is Negative. The current price of 39.76 is above the 20-day moving average (MA) of 29.69, above the 50-day MA of 33.88, and above the 200-day MA of 36.33, indicating a bearish trend. The MACD of -1.24 indicates Negative momentum. The RSI at 28.24 is Positive, neither overbought nor oversold. The STOCH value of 15.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3692.
Hansoh Pharmaceutical Group Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$173.80B | 28.25 | 16.71% | 0.97% | 22.62% | 26.23% | |
72 Outperform | HK$26.30B | 13.46 | 13.95% | 4.09% | 1.48% | -1.55% | |
63 Neutral | HK$24.22B | 14.99 | 8.65% | 2.26% | 10.00% | -7.54% | |
58 Neutral | HK$60.09B | 17.22 | 7.19% | 1.69% | 1.52% | 22.54% | |
58 Neutral | HK$27.08B | 6.21 | 7.98% | 2.95% | 4.66% | 20.76% | |
55 Neutral | HK$13.81B | 3.94 | 37.04% | ― | -13.04% | 1113.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3692
Hansoh Pharmaceutical Group Company Limited
30.32
0.90
3.06%
HK:0013
HUTCHMED (China)
16.77
-6.78
-28.79%
HK:0867
China Medical System Holdings
10.55
-1.15
-9.86%
HK:1513
Livzon Pharmaceutical Group
24.36
-3.37
-12.14%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
15.66
-0.90
-5.41%
HK:3320
China Resources Pharmaceutical Group Ltd.
4.41
-0.48
-9.80%
Hansoh Pharmaceutical Group Company Limited Corporate Events
Hansoh Pharmaceutical Shareholders Approve All Resolutions at 2026 AGM
Jun 26, 2026
Hansoh Pharmaceutical Group reported that all resolutions at its June 26, 2026 annual general meeting were approved by shareholders via poll, including adoption of the 2025 audited financial statements and the declaration of a final dividend, sign...
Hansoh Pharma Wins NMPA Nod to Review New Injection for Kidney-Disease Complication
Jun 10, 2026
Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted its New Drug Application for HS-10568 Injection, an innovative therapy for secondary hyperparathyroidism in adult chronic kidney disease patients underg...
Hansoh Pharmaceutical Reshapes Governance Team With New Joint Company Secretary
Jun 10, 2026
Hansoh Pharmaceutical has announced a change in its corporate governance team, with joint company secretary Zhong Shengli resigning effective June 10, 2026, after confirming she has no disagreements with the board or issues requiring shareholder a...
Hansoh Pharma Sets 2026 AGM to Approve 2025 Results, Dividend and Share Mandates
Jun 4, 2026
Hansoh Pharmaceutical Group has called its annual general meeting for June 26, 2026 in Hong Kong, where shareholders will review and adopt the 2025 audited financial statements and consider a proposed final dividend. The agenda also includes re-el...
Hansoh Pharma’s Weight-Loss Drug Olatorepatide Wins NDA Acceptance in China
Jun 3, 2026
Hansoh Pharmaceutical said China’s National Medical Products Administration has accepted its New Drug Application for Olatorepatide Injection, a self-developed, once-weekly GLP-1/GIP receptor dual agonist for chronic weight management in obe...
Hansoh Pharma Wins NMPA Breakthrough Status for Fourth-Gen Lung Cancer Drug
May 21, 2026
Hansoh Pharmaceutical Group has secured breakthrough-therapy designation from China’s National Medical Products Administration for HS-10504, its self-developed fourth-generation EGFR tyrosine kinase inhibitor. The oral therapy is proposed fo...
Hansoh Pharmaceutical Reshuffles Company Secretary and Compliance Roles
May 15, 2026
Hansoh Pharmaceutical Group announced board-level administrative changes, with joint company secretary, authorized representative and Hong Kong process agent Mr. Lee Leong Yin resigning effective May 15, 2026 due to personal work arrangements. The...
Hansoh Pharma Wins NMPA Nod for Trial of New KRAS-Targeting Cancer Drug
May 13, 2026
Hansoh Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of HS-10541 tablets, a self-developed Class 1 innovative drug. The therapy is designed for patients with KRAS G1...
Hansoh Pharmaceutical Wins Breakthrough Therapy Status for Esophageal Cancer ADC
May 11, 2026
Hansoh Pharmaceutical has received Breakthrough-Therapy-Designated Drug status from China’s National Medical Products Administration for HS-20093, a self-developed B7-H3-targeted antibody-drug conjugate for injection. The proposed indication...
Hansoh Pharmaceutical Expands RSU Share Pool With Market Purchases
Apr 30, 2026
Hansoh Pharmaceutical has disclosed that the trustee of its post-IPO restricted share unit scheme purchased 370,000 shares on the open market between April 14 and April 22, 2026, at an average price of about HK$39.11 per share, for a total conside...
Hansoh Hands KiOmed Osteoarthritis Licence to Hengrui in Strategic Refocus
Apr 29, 2026
Hansoh Pharmaceutical Group has transferred its exclusive Greater China licence for KiOmed Pharma’s osteoarthritis treatment KiOmedine vs One to Jiangsu Hengrui Pharmaceuticals, following a strategic review of its portfolio and resource allo...
Hansoh Pharma Wins China Nod for Trials of New Hypertension Drug HS-10522
Apr 29, 2026
Hansoh Pharmaceutical Group has announced that its self-developed Class 1 innovative drug candidate HS-10522 tablets has received two clinical trial approvals from China’s National Medical Products Administration. The approvals authorize cli...
Hansoh Pharma Wins Breakthrough Therapy Designation in China for Prostate Cancer ADC
Apr 29, 2026
Hansoh Pharmaceutical Group said its self-developed B7-H3-targeted antibody-drug conjugate HS-20093 has been granted Breakthrough-Therapy-Designated Drug status by China’s National Medical Products Administration. The proposed indication is ...
Hansoh Pharmaceutical Sets Final 2025 Dividend at HKD 0.20 Per Share
Apr 28, 2026
Hansoh Pharmaceutical Group has announced a final ordinary cash dividend of HKD 0.20 per share for the financial year ended 31 December 2025. The update mainly confirms the date for shareholders’ approval, which is set for 26 June 2026, alig...
Hansoh Pharma Grants 5 Million RSUs to Staff Under Post-IPO Incentive Scheme
Apr 28, 2026
Hansoh Pharmaceutical has granted 4,992,330 restricted share units under its post-IPO RSU scheme to 804 grantees, including one executive director and 803 employees, at a grant price of HK$7.8592 per share against a market price of HK$37.30. The a...
Hansoh Pharma Overhauls Equity Incentives With New 2026 Share Scheme
Apr 28, 2026
Hansoh Pharmaceutical Group has moved to overhaul its equity incentive framework by terminating its existing post-IPO restricted share unit scheme, originally adopted in 2019 and valid for ten years, ahead of schedule. Awards already granted under...
Hansoh Pharma Wins China Breakthrough Therapy Status for Lung Cancer ADC Combo
Apr 16, 2026
Hansoh Pharmaceutical Group has announced that its self-developed B7-H3-targeted antibody-drug conjugate HS-20093, administered by injection in combination with adebrelimab, has been granted Breakthrough-Therapy-Designated Drug status by ChinaR...
Hansoh Pharma Delivers Double-Digit 2025 Growth as Innovative Drugs Drive Earnings and Pipeline Wins
Mar 29, 2026
Hansoh Pharmaceutical Group reported strong 2025 results, with revenue rising 22.6% to RMB15.03 billion and profit up 27.1% to RMB5.56 billion, driven by a 30.4% surge in innovative and collaborative medicines, which now account for 82.2% of sales...
Hansoh Pharmaceutical Proposes HKD 0.20 Final Dividend for 2025
Mar 29, 2026
Hansoh Pharmaceutical Group Company Limited has proposed a final ordinary cash dividend of HKD 0.20 per share for the financial year ended 31 December 2025, reflecting the board’s decision to return cash to shareholders following its annual ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.